ValiRx - Strategy Update

Dr Suzy Dilly, Chief Executive Officer and Kevin Cox, Chairman of ValiRx, provide an update on the strategic direction of the company. Going forward ValiRx intends to build on its existing portfolio of drug candidates and grow a pipeline of innovative, early-stage projects in the areas of oncology and women's health. The Company plans to apply both intellectual and financial resources to each project and enable acceleration through pre-clinical development.

Suzanne Dilly
Chief Executive Officer
Dr Kevin Cox
Non-Executive Chairman

Company Events - VALIRX PLC